iOmx Therapeutics AG

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) ›

Areas of Activity ›

invIOs GmbH

Campus-Vienna-Biocenter 5 1030 Vienna Austria Peter Llewellyn-Davies +43-1-8656577 invios@invios.com www.invios.com

LI

35 2021

Immuno-Oncology

invIOs stands for innovative immuno-oncology (IO) and is focused on the discovery and development of cancer immunotherapies. invIOs is a fully owned subsidiary of APEIRON Biologics AG.

We are pioneers in the research & development of cell therapies targeting novel immune checkpoints and in immunomodulation.

Our Innovative Immuno-Oncology Pipeline

Despite successes with current therapies such as immune checkpoint inhibitors, there are large numbers of non-responders and patients who relapse following treatment. Due to these limitations, there is a huge demand for novel tumour therapies. The invIOs pipeline currently comprises two autologous cell therapy projects based on a platform technology targeting the master checkpoint inhibitor Cbl-b, as well as one small molecule asset.

› APN401 is an out-patient cell therapy with a very short needle-to-needle treatment time. Based on our platform technology, Cbl-b is silenced in white blood cells, thus leading to a highly specific activation of innate and adaptive immune responses. It is our lead project, currently being evaluated in a clinical Phase Ib trial in patients with advanced solid tumours. › APN441 is a tumor-specific cell therapy approach utilizing our platform technology and Cbl-b to activate local, tumor-associated tumor infiltrating lymphocytes (TILs). It is in an early development stage for patients with glioblastoma. › INV501 is a novel small molecule candidate intended to activate anti-tumour immune responses and addresses a novel, undisclosed IO target.

Our lead project APN401 – a siRNAbased cell therapy targeting Cbl-b

The discovery of a new “master” regulator of immunecell activation has been proven to help override negative signals to activate immune cells. Cbl-b is an intracellular protein that can be silenced in immune cells, triggering their re-activation. It has been shown that the blockade of Cbl-b activates immune cells and enables them to destroy cancerous cells. We have developed a proprietary platform technology process targeting Cbl-b and potentially other checkpoints in human cells from patients.

The clinical programme APN401 is a first-in-class out-patient approach to strengthen immune reactivity through Cbl-b silencing. In a first-in-human study, the treatment was safe and well tolerated. Silencing Cbl-b could provide a revolutionary new treatment to awaken anti-tumour responses, providing new hope for patients with various tumours, as monotherapy but also in combination with other approaches.

APN401 is the first clinical candidate based on our cell therapy platform. It enables rapid treatment of patients using their own immune cells for reactivation in an outpatient setting. The novel concept allows access to and treatment for indications that had not previously been addressable by cell therapy.

Our Innovation Hub: dedicated to delivering lifesaving medicines in IO

A crucial part of our business model for value growth is our Innovation Hub. The goal is to accelerate promising drug candidates to tangible value points. We are continuously scouting for promising innovative early-stage projects in the field of immuno-oncology and will advance them into next-generation therapies until clinical proof of concept. With full-range in-house development capabilities (preclinical and clinical) and a seasoned and dedicated team, invIOs accelerates projects with entrepreneurial excellence.